The present invention is related to novel compounds of formula (I) having equilibrative nucleoside transporter ENT1 inhibiting properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the inhibition of ENT1 receptors in animals, in particular humans.
PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS
申请人:TMEM16A LIMITED
公开号:US20220235006A1
公开(公告)日:2022-07-28
Compounds of general formula (I), wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
and R
10
are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
US8263592B2
申请人:——
公开号:US8263592B2
公开(公告)日:2012-09-11
[EN] PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS<br/>[FR] DÉRIVÉS DE PYRIDINE UTILISÉS EN TANT QUE MODULATEURS DE TMEM16A DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS RESPIRATOIRES
申请人:ENTERPRISE THERAPEUTICS LTD
公开号:WO2021014166A1
公开(公告)日:2021-01-28
Compounds of general formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.